Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Get Rating) Director Thomas John Dietz acquired 50,000 shares of Eiger BioPharmaceuticals stock in a transaction on Monday, January 23rd. The shares were bought at an average cost of $1.43 per share, with a total value of $71,500.00. Following the completion of the transaction, the director now owns 50,000 shares of the company’s stock, valued at $71,500. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Thomas John Dietz also recently made the following trade(s):
- On Thursday, December 22nd, Thomas John Dietz sold 22,500 shares of Eiger BioPharmaceuticals stock. The shares were sold at an average price of $1.17, for a total transaction of $26,325.00.
Eiger BioPharmaceuticals Price Performance
EIGR traded down $0.05 on Wednesday, hitting $1.37. 292,723 shares of the stock were exchanged, compared to its average volume of 590,720. The company has a debt-to-equity ratio of 0.50, a current ratio of 5.45 and a quick ratio of 5.34. Eiger BioPharmaceuticals, Inc. has a 12 month low of $0.96 and a 12 month high of $10.02. The firm has a market capitalization of $60.38 million, a price-to-earnings ratio of -0.57 and a beta of 1.64. The business has a 50-day moving average of $2.14 and a two-hundred day moving average of $5.44.
Wall Street Analysts Forecast Growth
EIGR has been the subject of several research reports. Citigroup dropped their price target on Eiger BioPharmaceuticals from $23.00 to $4.00 in a report on Friday, December 9th. StockNews.com cut shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, November 4th. BTIG Research lowered their price target on shares of Eiger BioPharmaceuticals from $48.00 to $9.00 in a research report on Monday, December 12th. Finally, Robert W. Baird cut their price objective on shares of Eiger BioPharmaceuticals from $29.00 to $3.00 in a report on Friday, December 9th.
Hedge Funds Weigh In On Eiger BioPharmaceuticals
A number of institutional investors have recently modified their holdings of the business. Sigma Planning Corp raised its stake in Eiger BioPharmaceuticals by 2.2% during the second quarter. Sigma Planning Corp now owns 63,700 shares of the biotechnology company’s stock worth $401,000 after acquiring an additional 1,400 shares in the last quarter. Legal & General Group Plc lifted its stake in Eiger BioPharmaceuticals by 62.0% in the 2nd quarter. Legal & General Group Plc now owns 4,327 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 1,656 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Eiger BioPharmaceuticals by 2.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 88,711 shares of the biotechnology company’s stock valued at $737,000 after buying an additional 1,953 shares in the last quarter. Nuveen Asset Management LLC grew its stake in shares of Eiger BioPharmaceuticals by 2.3% during the third quarter. Nuveen Asset Management LLC now owns 102,103 shares of the biotechnology company’s stock worth $768,000 after buying an additional 2,309 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Eiger BioPharmaceuticals by 2.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 114,658 shares of the biotechnology company’s stock valued at $722,000 after acquiring an additional 2,537 shares in the last quarter. Institutional investors and hedge funds own 69.08% of the company’s stock.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
- Get a free copy of the StockNews.com research report on Eiger BioPharmaceuticals (EIGR)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.